MX2019012749A - Metodos para tratar trastornos pediatricos. - Google Patents

Metodos para tratar trastornos pediatricos.

Info

Publication number
MX2019012749A
MX2019012749A MX2019012749A MX2019012749A MX2019012749A MX 2019012749 A MX2019012749 A MX 2019012749A MX 2019012749 A MX2019012749 A MX 2019012749A MX 2019012749 A MX2019012749 A MX 2019012749A MX 2019012749 A MX2019012749 A MX 2019012749A
Authority
MX
Mexico
Prior art keywords
vedolizumab
integrin
beta
alpha
antibodies specific
Prior art date
Application number
MX2019012749A
Other languages
English (en)
Inventor
Rosario Maria
A Shetzline Michael
R Treem William
Original Assignee
Millennium Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Millennium Pharm Inc filed Critical Millennium Pharm Inc
Publication of MX2019012749A publication Critical patent/MX2019012749A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1777—Integrin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pain & Pain Management (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Rheumatology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La invención proporciona métodos para el tratamiento de pacientes pediátricos con enfermedad intestinal inflamatoria mediante el uso de vedolizumab.
MX2019012749A 2017-04-28 2018-04-26 Metodos para tratar trastornos pediatricos. MX2019012749A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762492031P 2017-04-28 2017-04-28
PCT/US2018/029579 WO2018200818A2 (en) 2017-04-28 2018-04-26 Method of treating pediatric disorders

Publications (1)

Publication Number Publication Date
MX2019012749A true MX2019012749A (es) 2020-02-03

Family

ID=62455814

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019012749A MX2019012749A (es) 2017-04-28 2018-04-26 Metodos para tratar trastornos pediatricos.

Country Status (12)

Country Link
US (1) US20200179486A1 (es)
EP (1) EP3615071A2 (es)
JP (2) JP2020517671A (es)
KR (1) KR20190141148A (es)
CN (1) CN110612120A (es)
AR (1) AR111491A1 (es)
AU (1) AU2018256840A1 (es)
BR (1) BR112019022268A2 (es)
CA (1) CA3061320A1 (es)
MX (1) MX2019012749A (es)
TW (2) TWI811216B (es)
WO (1) WO2018200818A2 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170327584A1 (en) 2014-11-26 2017-11-16 Millennium Pharmaceuticals, Inc. Vedolizumab for the Treatment of Fistulizing Crohn's Disease

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
WO1988007089A1 (en) 1987-03-18 1988-09-22 Medical Research Council Altered antibodies
JP3095168B2 (ja) 1988-02-05 2000-10-03 エル． モリソン，シェリー ドメイン‐変性不変部を有する抗体
AU691811B2 (en) 1993-06-16 1998-05-28 Celltech Therapeutics Limited Antibodies
US5840299A (en) 1994-01-25 1998-11-24 Athena Neurosciences, Inc. Humanized antibodies against leukocyte adhesion molecule VLA-4
US7803904B2 (en) 1995-09-01 2010-09-28 Millennium Pharmaceuticals, Inc. Mucosal vascular addressing and uses thereof
AU4986296A (en) 1995-02-10 1996-08-27 Leukosite Incorporated Mucosal vascular addressins and uses thereof
US7147851B1 (en) 1996-08-15 2006-12-12 Millennium Pharmaceuticals, Inc. Humanized immunoglobulin reactive with α4β7 integrin
US6197582B1 (en) 1998-03-18 2001-03-06 The Trustees Of Columbia University In The City Of New York Development of human monoclonal antibodies and uses thereof
EP2399903A1 (en) 2002-05-24 2011-12-28 Millennium Pharmaceuticals, Inc. Ccr9 inhibitors and methods of use thereof
ES2286502T3 (es) 2002-11-18 2007-12-01 Chemocentryx, Inc. Sulfonamidas de arilo.
HUE058817T2 (hu) 2004-09-03 2022-09-28 Genentech Inc Humanizált anti-béta7 antagonisták és alkalmazásaik
CA2629147A1 (en) 2005-11-17 2007-05-31 Millennium Pharmaceuticals, Inc. Humanized immunoglobulin reactive with .alpha.4.beta.7 integrin
ES2751946T3 (es) 2009-03-20 2020-04-02 Amgen Inc Anticuerpo antagonista específico del heterodímero alfa-4-beta-7
KR102014512B1 (ko) 2011-05-02 2019-08-26 밀레니엄 파머슈티컬스 인코퍼레이티드 항-α4β7 항체에 대한 제형
UA116189C2 (uk) * 2011-05-02 2018-02-26 Мілленніум Фармасьютікалз, Інк. КОМПОЗИЦІЯ АНТИ-α4β7 АНТИТІЛА
JP2018507868A (ja) * 2015-02-26 2018-03-22 ジェネンテック， インコーポレイテッド インテグリンベータ７アンタゴニスト及びクローン病の治療方法
CN117298268A (zh) * 2016-03-14 2023-12-29 千禧制药公司 治疗或预防移植物抗宿主疾病的方法

Also Published As

Publication number Publication date
CN110612120A (zh) 2019-12-24
TWI811216B (zh) 2023-08-11
WO2018200818A3 (en) 2018-12-06
TW202342102A (zh) 2023-11-01
EP3615071A2 (en) 2020-03-04
CA3061320A1 (en) 2018-11-01
JP2023113655A (ja) 2023-08-16
BR112019022268A2 (pt) 2020-05-19
US20200179486A1 (en) 2020-06-11
AR111491A1 (es) 2019-07-17
WO2018200818A9 (en) 2019-01-17
KR20190141148A (ko) 2019-12-23
RU2019138312A (ru) 2021-05-28
RU2019138312A3 (es) 2022-02-03
WO2018200818A2 (en) 2018-11-01
AU2018256840A1 (en) 2019-11-07
JP2020517671A (ja) 2020-06-18
TW201842932A (zh) 2018-12-16

Similar Documents

Publication Publication Date Title
HRP20181796T1 (hr) Derivati naftiridina kao antagonisti alfa v beta 6 integrina, namijenjeni liječenju, primjerice, fibrotičnih bolesti
SG10201903823QA (en) Methods and compositions relating to microbial treatment and diagnosis of disorders
MY188940A (en) Anti-pd-l1 antibodies and diagnostic uses thereof
PH12018500887A1 (en) Anti-htra1 antibodies and methods of use thereof
IL279260A (en) KDM1A inhibitors for the treatment of diseases
IL277217A (en) Use of anti-IL-36R antibodies to treat inflammatory bowel disease
SG11202107978RA (en) Methods and system for the reconstruction of drug response and disease networks and uses thereof
MX2023003519A (es) Anticuerpo anti-semaforina 4d humano.
MX2022002056A (es) Compuestos para el tratamiento de enfermedad respiratoria bovina o porcina.
IL276896A (en) Methods for treating Crohn's disease with a specific anti-IL23 antibody
EP3585818A4 (en) ANTI-HLA-DQ2.5 / 8 ANTIBODIES AND ITS USE FOR THE TREATMENT OF C LIATIC DISEASE
PH12019500434A1 (en) Anti-gm-csf antibodies and uses thereof
MA41090A (fr) Antagoniste de a2a faiblement dosé pour le traitement du tdah et de la maladie de parkinson
MX2019012749A (es) Metodos para tratar trastornos pediatricos.
GB201808575D0 (en) Methods for the treatment of psoriatic arthrits
MX2019010060A (es) Composiciones y metodo para tratar cancer.
MX2017003014A (es) Anticuerpos anti-alfa v beta 5 humanizados y usos de estos.
MX2017010306A (es) Bloqueadores del receptor de la hormona del crecimiento en la prevencion y tratamiento de enfermedades.
EP3958754C0 (fr) Dispositif pour le traitement de la maladie hemorroïdaire
MX2019014475A (es) Formulaciones de lixivaptan para el tratamiento de enfermedades poliquisticas.
IL274536A (en) Methods for prognosis or treatment of parkinson's disease
HUP1800440A2 (hu) In vitro eljárás rosszindulatú állapotok diagnosztizálására
GB201911728D0 (en) Bacterial composistions for the treatment of disease
SG11202106912WA (en) Anti-ephrin-b2 blocking antibodies for the treatment of fibrotic diseases
UA106740U (uk) Спосіб прогнозування зрощення перелому